These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 31491880

  • 1. A Molecular Dynamics Study of Vasoactive Intestinal Peptide Receptor 1 and the Basis of Its Therapeutic Antagonism.
    Latek D, Langer I, Krzysko K, Charzewski L.
    Int J Mol Sci; 2019 Sep 05; 20(18):. PubMed ID: 31491880
    [Abstract] [Full Text] [Related]

  • 2. Drug Repositioning For Allosteric Modulation of VIP and PACAP Receptors.
    Langer I, Latek D.
    Front Endocrinol (Lausanne); 2021 Sep 05; 12():711906. PubMed ID: 34867774
    [Abstract] [Full Text] [Related]

  • 3. VPAC1 receptor binding site: contribution of photoaffinity labeling approach.
    Couvineau A, Ceraudo E, Tan YV, Laburthe M.
    Neuropeptides; 2010 Apr 05; 44(2):127-32. PubMed ID: 20031208
    [Abstract] [Full Text] [Related]

  • 4. VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins.
    Couvineau A, Laburthe M.
    Br J Pharmacol; 2012 May 05; 166(1):42-50. PubMed ID: 21951273
    [Abstract] [Full Text] [Related]

  • 5. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D, Anouar Y, Jegou S, Fournier A, Vaudry H.
    Endocrinology; 1999 Mar 05; 140(3):1285-93. PubMed ID: 10067855
    [Abstract] [Full Text] [Related]

  • 6. Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology.
    Laburthe M, Couvineau A, Tan V.
    Peptides; 2007 Sep 05; 28(9):1631-9. PubMed ID: 17574305
    [Abstract] [Full Text] [Related]

  • 7. Peptide agonist docking in the N-terminal ectodomain of a class II G protein-coupled receptor, the VPAC1 receptor. Photoaffinity, NMR, and molecular modeling.
    Tan YV, Couvineau A, Murail S, Ceraudo E, Neumann JM, Lacapère JJ, Laburthe M.
    J Biol Chem; 2006 May 05; 281(18):12792-8. PubMed ID: 16520374
    [Abstract] [Full Text] [Related]

  • 8. Strategies for studying the ligand binding site of GPCRs: photoaffinity labeling of the VPAC1 receptor, a prototype of class B GPCRs.
    Couvineau A, Tan YV, Ceraudo E, Laburthe M.
    Methods Enzymol; 2013 May 05; 520():219-37. PubMed ID: 23332702
    [Abstract] [Full Text] [Related]

  • 9. Endogenous inhibition of hippocampal LTD and depotentiation by vasoactive intestinal peptide VPAC1 receptors.
    Cunha-Reis D, Aidil-Carvalho Mde F, Ribeiro JA.
    Hippocampus; 2014 Nov 05; 24(11):1353-63. PubMed ID: 24935659
    [Abstract] [Full Text] [Related]

  • 10. The human VPAC1 receptor: identification of the N-terminal ectodomain as a major VIP-binding site by photoaffinity labeling and 3D modeling.
    Couvineau A, Tan YV, Ceraudo E, Lacapère JJ, Murail S, Neumann JM, Laburthe M.
    Ann N Y Acad Sci; 2006 Jul 05; 1070():205-9. PubMed ID: 16888167
    [Abstract] [Full Text] [Related]

  • 11. 3D structure prediction of VAPC1 and identification of dual natural inhibitors for VPAC1 and EGFR.
    Sarkar A, Sen S.
    J Bioenerg Biomembr; 2019 Apr 05; 51(2):89-102. PubMed ID: 30810849
    [Abstract] [Full Text] [Related]

  • 12. The VPAC1 receptor: structure and function of a class B GPCR prototype.
    Couvineau A, Ceraudo E, Tan YV, Nicole P, Laburthe M.
    Front Endocrinol (Lausanne); 2012 Apr 05; 3():139. PubMed ID: 23162538
    [Abstract] [Full Text] [Related]

  • 13. The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics.
    Ceraudo E, Murail S, Tan YV, Lacapère JJ, Neumann JM, Couvineau A, Laburthe M.
    Mol Endocrinol; 2008 Jan 05; 22(1):147-55. PubMed ID: 17885205
    [Abstract] [Full Text] [Related]

  • 14. Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation.
    St Hilaire RC, Murthy SN, Kadowitz PJ, Jeter JR.
    Peptides; 2010 Aug 05; 31(8):1517-22. PubMed ID: 20452385
    [Abstract] [Full Text] [Related]

  • 15. Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.
    Reubi JC, Läderach U, Waser B, Gebbers JO, Robberecht P, Laissue JA.
    Cancer Res; 2000 Jun 01; 60(11):3105-12. PubMed ID: 10850463
    [Abstract] [Full Text] [Related]

  • 16. Vasoactive intestinal peptide (VIP) stimulates cortisol secretion from the H295 human adrenocortical tumour cell line via VPAC1 receptors.
    Nicol MR, Cobb VJ, Williams BC, Morley SD, Walker SW, Mason JI.
    J Mol Endocrinol; 2004 Jun 01; 32(3):869-77. PubMed ID: 15171718
    [Abstract] [Full Text] [Related]

  • 17. Vasoactive intestinal polypeptide VPAC1 and VPAC2 receptor chimeras identify domains responsible for the specificity of ligand binding and activation.
    Juarranz MG, Van Rampelbergh J, Gourlet P, De Neef P, Cnudde J, Robberecht P, Waelbroeck M.
    Eur J Biochem; 1999 Oct 01; 265(1):449-56. PubMed ID: 10491203
    [Abstract] [Full Text] [Related]

  • 18. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland.
    Mazzocchi G, Malendowicz LK, Neri G, Andreis PG, Ziolkowska A, Gottardo L, Nowak KW, Nussdorfer GG.
    Int J Mol Med; 2002 Mar 01; 9(3):233-43. PubMed ID: 11836629
    [Abstract] [Full Text] [Related]

  • 19. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
    Summers MA, O'Dorisio MS, Cox MO, Lara-Marquez M, Goetzl EJ.
    J Pharmacol Exp Ther; 2003 Aug 01; 306(2):638-45. PubMed ID: 12750439
    [Abstract] [Full Text] [Related]

  • 20. Evidence for the involvement of VPAC1 and VPAC2 receptors in pressure-induced vasodilatation in rodents.
    Fizanne L, Sigaudo-Roussel D, Saumet JL, Fromy B.
    J Physiol; 2004 Jan 15; 554(Pt 2):519-28. PubMed ID: 14578481
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.